PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1
Open Access
- 5 June 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 597, 217007
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cellsCancer Letters, 2023
- CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancerCancer Letters, 2023
- MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cellsCancer Letters, 2023
- MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancerCancer Letters, 2023
- SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activityCancer Letters, 2022
- Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast‐secreted factors through the HGF/C‐MET axisInternational Journal of Cancer, 2022
- KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitorsMolecular Oncology, 2022
- KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysisInternational Journal of Colorectal Disease, 2021
- Targeting the MAPK Pathway in KRAS-Driven TumorsCancer Cell, 2020
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal CancerCancer Cell, 2019